Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;36(7):10.1002/jcla.24492.
doi: 10.1002/jcla.24492. Epub 2022 May 16.

Serum transfer RNA-derived fragment tRF-31-79MP9P9NH57SD acts as a novel diagnostic biomarker for non-small cell lung cancer

Jipeng Li  1 , Chao Cao  2 , Laifu Fang  3 , Wanjun Yu  4
Affiliations

Serum transfer RNA-derived fragment tRF-31-79MP9P9NH57SD acts as a novel diagnostic biomarker for non-small cell lung cancer

Jipeng Li et al. J Clin Lab Anal. 2022 Jul.

Abstract

Background: tRNA-derived fragments (tRFs) have been found to have a crucial function in the pathophysiology of cancers. However, the function of tRFs in non-small cell lung cancer (NSCLC) is yet unknown. The goal of this study was to assess the tRF-31-79MP9P9NH57SD serum expression from NSCLC patients and to determine its diagnostic usefulness.

Methods: By using stem-loop quantitative real-time PCR, we were able to detect various tRF-31-79MP9P9NH57SD expressions in 96 NSCLC serum samples, 96 healthy controls, and 20 pairs of NSCLC serum samples pre- and post-surgery (qRT-PCR). After that, we analyzed its diagnostic effectiveness using the receiver operating characteristic (ROC) curve.

Results: Serum tRF-31-79MP9P9NH57SD expression was higher in NSCLC patients, and levels of tRF-31-79MP9P9NH57SD were linked to the clinical stage (p = 0.002) and the malignancy of lymph node (p = 0.012). In addition, after the procedure, the serum tRF-31-79MP9P9NH57SD expression in NSCLC patients dropped. With 48.96 percent sensitivity and 90.62 percent specificity, the area under ROC curve (AUC) was 0.733.

Conclusion: serum tRF-31-79MP9P9NH57SD possibly is a new and groundbreaking biomarker for the NSCLC.

Keywords: NSCLC; biomarker; tRF-31-79MP9P9NH57SD; tRNA-derived small RNAs.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

FIGURE 1
FIGURE 1
Characteristics of the tRF‐31‐79MP9P9NH57SD. (A) tRF‐31‐79MP9P9NH57SD is a form of 5’‐tRF with a length of 31 nt. (B) tRF‐31‐79MP9P9NH57SD is derived from mature tRNAVal‐CAC. (C) The PCR melting curve of tRF‐31‐79MP9P9NH57SD. (D) Sanger sequencing was used to validate the qRT‐PCR product
FIGURE 2
FIGURE 2
Highly expressed tRF‐31‐79MP9P9NH57SD in serum of NSCLC patients. (A) Stem‐loop qRT‐PCR detected a comparison of tRF‐31‐79MP9P9NH57SD expression between NSCLC patients and healthy human subjects. (B) The tRF‐31‐79MP9P9NH57SD amount in paired pre‐ and post‐surgical samples
FIGURE 3
FIGURE 3
ROC curve assessed the diagnostic value of serum tRF‐31‐79MP9P9NH57SD, NSE, CYFRA21‐1, and the combination of these biomarkers (Panel) in NSCLC
FIGURE 4
FIGURE 4
Investigation of the downstream and role estimation of tRF‐31‐79MP9P9NH57SD. (A) Possible targeted genes of tRF‐31‐79MP9P9NH57SD as anticipated by TargetScan, miRanda, and TargetRank. (B) KEGG pathway analysis of tRF‐31‐79MP9P9NH57SD. (C) GO enrichment analysis of tRF‐31‐79MP9P9NH57SD
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7‐30. - PubMed
    1. Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non‐small cell lung cancer: a review. JAMA. 2019;322(8):764‐774. - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‐424. - PubMed
    1. Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019;16(6):341‐355. - PubMed
    1. Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non‐small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52(Pt 1):103‐109. - PMC - PubMed

MeSH terms